UNEEG has now accumulated more than 450,000 hours of real-world EEG, including 10,000 annotated seizures and 150,000 hours of sleep data. This unprecedented dataset continues to grow.

An investor-sponsored study in Italy has begun exploring pediatric use, including the first child implanted with our device.

The 24/7 SubQ system receives EU Approval for 3-Year Continuous Use of UNEEG SubQ Implant

Winner of the Red dot award - Product design concept within the category Medical Devices and Technology

EU MDR certificate achieved for the UNEEG SubQ implant.

UNEEG EpiSight solution is granted FDA Breakthrough Device Designation within monitoring and diagnostic of epilepsy.

Launch of UNEEG EpiSight – subcutaneous, ultra long-term, wireless EEG recording.

UNEEG medical and King’s College London are awarded £1.8 million in the i4i Challenge Awards Call from the National Institute for Health and Care Research (NIHR) in the UK to conduct a multicentre, observational cohort study of the 24/7 EEG SubQ solution.

Our UNEEG™ MyConnect data-transfer solution is launched. With MyConnect, for the first time EEG data are automatically sent from the patient to the hospital.

First US patient initiated in pivotal multi-centre study for US approval of 24/7 EEG SubQ solution. The study is conducted at the University of Pennsylvania (US), Mayo Clinic (US) and Freiburg University Hospital (Germany)

Pivotal study “ultra long-term subcutaneous home monitoring of epilepsy - 490 days of EEG from nine patients” is published in Epilepsia. The study is the first real-life monitoring of EEG in people with epilepsy; study participants record EEG data in their home environment with the 24/7 EEG SubQ. The study demonstrates that objective, real-life electrographic seizure counting can be obtained from subcutaneous EEG recordings. The study further concludes a substantial difference between the patient’s self-reported seizure counts and the objective seizure counts recorded with our solution.

First UK patient implanted with the UNEEG SubQ as part of a USD 3 million programme funded by the Epilepsy Foundation of America as part of the project “My Seizure Gauge”.

We receive ethics approval to initiate an ultra long-term sleep monitoring trial under the heading “Sleep in the ultra long-term perspective: Seasonally and behaviourally induced variation”.

The 24/7 SubQ system is CE-marked, a major step forward in achieving our commercial ambitions.

UNEEG launches a strategic partnership with the Austrian Institute of Technology, which obtains a CE-mark on a specialized 2-channel version of their encevis software that includes an algorithm for seizure detection.

The study ”High similarity between EEG from subcutaneous and proximate scalp electrodes in patients with temporallobe epilepsy” is published, and shows that electrographic seizures can be monitored with the 24/7 SubQ.

Our ultra long-term EEG technology receives the prestigious Shark Tank Prize from the US Epilepsy Foundation of America. The prize is awarded to the most innovative idea that can help those living with epilepsy.

We change our name to UNEEG Medical.

Pivotal paper ”EEG signal quality of a subcutaneous recording system compared to standard surface electrodes” shows that the signal quality of our implant at least equals that of scalp EEG.

UNEEG conducts its first in man study - a major milestone, opening the path towards larger clinical trials.

First epilepsy PhD research project is initiated under the title “Detection and Prediction of Epileptic Seizures”.

Widex Holding becomes the majority shareholder of Hypo-Safe A/S. Widex Holding brings a vast experience in design, manufacturing and marketing of miniaturized medical devices to the company.

The company Hypo-Safe A/S is founded by Professor dr. med. Henning Beck-Nielsen and co-founder, engineer Rasmus Stig Jensen. The original concept was designed to detect hypoglycemia in people with type 1 diabetes by monitoring brain activity. As the technology matured, the team discovered the implant could deliver high-quality signals over long periods - leading the founders to reassess where the technology could have the greatest clinical impact.